Audit: QRS - Cnidium monnieri for Health & Longevity
Audit conducted on 17/08/2026 18:37 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 88 |
| Failed | 0 |
| N/A | 5 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All doses (3–10 g, 15–30 g, 250–500 mg 10:1, 10–98%), all biomarker targets, the cadence, both time-to-effect values, and every gate/benefit/risk item trace to explicit ER text. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No dose has been validated in a controlled human trial” and “No human time-course exists” carry the ER’s hedges verbatim. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain contraindications; cautions remain cautions; tier assignments match the ER exactly. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates draw only from Key Interactions & Contraindications; Benefits/Risks only from their own ER sections; no modifying factor is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT numbers, author names, or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No institutions, practitioners, or organisations are named. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s sceptical, mechanism-aware register — preclinical claims flagged as such throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and tiered evidence let a reader act on the material; nothing is alarmist or moralising. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents ranges and thresholds without issuing orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Descriptive throughout; the footer disclaimer is the template’s own. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “should”, “recommended”, or “advised” appears in the QRS’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the rendered text. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to the places they carry information (CYP enzymes, furanocoumarins, biomarker names). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items, tier lines, and marker rows are stripped to key facts. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed; no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional-range biomarker targets and a bone-turnover panel presuppose exactly this audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Decoctions, sitz baths, night-time application, and repeat laboratory panels are presented without apology. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification toward mass-market framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance foregrounds the adulteration and phototoxicity ledger that matters most to a self-directed user. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “erectile response”, “phototoxic”, “contraindications”, “transaminases”; the plain-language wording in At-A-Glance is required by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings, gate headings, tier labels, and table headers are byte-identical to the template. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Every template span is present; the marker_#_* and qualitative_item_# families are expanded to 8 and 6 numbered instances respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A full diff against the template shows changes confined to variable content, the two display: none tier spans, and the hidden time_3 cell. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section feeding the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels (“Traditional oral dose”, “Traditional external protocol”, “Extract equivalents”) and eight of the nine caution items reuse the ER bold labels verbatim; the ninth replaces the ER’s catch-all container label “Other interventions” with the interaction itself, as item 9.5 requires the substantive content be preserved. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented labels; marker names match the ER biomarker table exactly. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the file; tiers are conveyed by bold labels plus the green/red card CSS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content is condensed to the minimum permitted by the mandatory-completeness items (14.2, 15.2, 8.5, 9.5); the print rules and A4 @page sizing are intact. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no corresponding visible element exists. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, and it contains a colon requiring it. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: cnidium_monnieri_2026-0825-1350_Opus_ER.md, line 4. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02, matching the QRS.md badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0817-1816. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus, line 7. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5, line 8. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no context-window or other qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: cnidium_monnieri_2026-0825-1350_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Cnidium monnieri for Health & Longevity - Quick Reference Sheet”, line 22. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Cnidium monnieri for Health & Longevity”, line 417. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0817-1816 → “08/17/2026”, line 421. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5”, line 425. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Mirrors the Conclusion’s structure: traditional record, the topical-only human evidence, preclinical bone/erectile claims, and the safety ledger. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion sentence; “most sexual-performance products tested” tracks the ER’s own “most products tested were found to contain undeclared prescription drugs”. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “sun-sensitising compounds” for furanocoumarins, “a liver signal”, “slowed drug clearance”; no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Only the qualitative “modest improvement”; no SMD, RR, or percentages. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items come from that section’s “Populations who should avoid” list plus its absolute-contraindication nitrate bullet. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER avoid-populations are represented, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven <li> elements inside the span, lines 565–574. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing clauses (“— no safety data at any dose…”, “where clearance is substantially impaired”, “given the adulteration risk…”) are all stripped; no dashes remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “above twice the upper limit of normal”, “Child-Pugh Class B or C”, the named nitrates and photosensitivity disorders, and “within two weeks of scheduled surgery” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | The ER uses no ranking notation here; all parentheticals are plain comma-separated lists. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER identifies seven such populations, and the section is correctly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map one-to-one onto ER caution bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | The ER’s ten interaction bullets less the nitrate bullet (carried as an absolute contraindication) yields exactly the nine listed. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine <li> elements, lines 582–600. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER mitigation clause (“Mitigation: check the international normalised ratio…”, “separate topical application from sun exposure…”) is stripped; no dashes remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All named example drugs are preserved, including the three-way grouped supplement list and “high-dose paracetamol”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking symbols in the ER; parentheticals are plain comma- and semicolon-separated lists. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies ten such interactions, and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol bullets. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Oral dose, external protocol, and extract equivalents are the three dose-determining bullets; the remaining bullets are modifiers rather than actions. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three distinct actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Nine populated spans, all ER-derived: 3–10 g, 15–30 g, 250–500 mg 10:1, split dosing with food, night-time topical application, 10–98% purity. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The ER’s Practical Considerations “Time to effect” bullet yields exactly two distinct aspects — topical antipruritic and oral/bone — and both are carried. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Topical itch relief (Medium tier) precedes bone effects (Low tier). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | The third pcell carries style="display: none" with all three spans emptied, lines 522–532. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “1–2 weeks” and the two-month rodent time-course both match the ER verbatim. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All nine benefit headings from the ER are represented at their ER tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present, lines 540–555. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | ER headings condensed to bare phrases; no Magnitude figures (SMD −0.35, RR 1.29, SMD 3.08, 0.1–30 μM) carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High-tier benefit; benefits_high is emptied and set to display: none, line 540. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eight risk headings from the ER are represented at their ER tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present, lines 612–630. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Condensed ER headings only; the 61%/150-product figures and the 21.9/18.1/13.1 μM inhibition constants are not carried over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks span. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High-tier risk; risks_high is emptied and set to display: none, line 612. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence both come from the ER Monitoring Protocol & Defining Success section. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER table rows are present in ER order — ALT, AST, GGT, INR, 25-hydroxyvitamin D, Serum CTX, P1NP, seated blood pressure — with targets and rationales matching. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Baseline, 6 weeks, 12 weeks, 1 and 4 weeks for anticoagulation, 6 months for bone turnover, then 6–12 months — matching the ER paragraph. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are carried, in ER order and near-verbatim. |
Issues 17/08/2026 18:37
Pass rate 100.00%. No issues found.
Issues 17/08/2026 18:30
- 11.1 / 11.3 — Third time-to-effect set not a time-to-effect aspect: The ER supplies only two time-to-effect aspects (“Time to effect” in Practical Considerations: topical 1–2 weeks and oral/bone “a quarter at minimum”), yet time_3 (lines 524–533) is filled with “Suggested duration / 8–12 weeks oral” drawn from
Discontinuation & Cycling; the unused third set should instead be left empty and made invisible.
Fixes 17/08/2026 18:30
- 11.1 / 11.3 — Third time-to-effect set emptied: Removed the “Suggested duration / 8–12 weeks oral” content from time_3, which came from
Discontinuation & Cyclingrather than the ER’s time-to-effect material, and left the three time_3 spans empty with the surrounding.pcellset todisplay: none.
Issues 17/08/2026 18:23
- 8.4 — Redundant trailing clause on nitrates: The nitrates contraindication at QRS lines 571–574 ends with “, including nitrate therapy for angina”, a trailing elaboration already covered by the head term “Nitrates and nitric oxide donors (nitroglycerin, isosorbide, amyl nitrite)”.
Fixes 17/08/2026 18:23
- 8.4 — Redundant trailing clause on nitrates: Stripped “, including nitrate therapy for angina” from the nitrates contraindication, leaving “Nitrates and nitric oxide donors (nitroglycerin, isosorbide, amyl nitrite)”.